{
    "clinical_study": {
        "@rank": "58827", 
        "arm_group": [
            {
                "arm_group_label": "Ubiquinone", 
                "arm_group_type": "Experimental", 
                "description": "400mg daily of oral ubiquinone for 24 weeks"
            }, 
            {
                "arm_group_label": "Combined antioxidant therapy", 
                "arm_group_type": "Experimental", 
                "description": "(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo. 100mg daily oral intake for 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of ubiquinone and combined antioxidant\n      therapy on progression, clinical regression, oxidative stress markers and mitochondrial\n      dysfunction in non-proliferative diabetic retinopathy."
        }, 
        "brief_title": "Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Non-proliferative Diabetic Retinopathy", 
            "Diabetes Mellitus Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Retinopathy", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Retinal Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators are interested in  demonstrating the efficacy of Ubiquinone and combined\n      antioxidant therapy in the pharmacological management of diabetic retinopathy since early\n      stages."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with type 2 diabetes mellitus\n\n          -  Patients with non proliferative diabetic retinopathy\n\n          -  Glycated hemoglobin < 12.0%\n\n          -  Signing of informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with clinically significant macular edema\n\n          -  Patients with diabetic retinopathy advanced lesions that have required or require\n             specific treatment (laser, vitrectomy)\n\n          -  Pretreatment with argon laser or excimer laser Ophthalmology surgery\n\n          -  Any other associated ocular pathology (glaucoma, cataracts, changing cornea\n             dystrophy, macular degeneration)\n\n          -  Pregnancy, lactation, inadequate use of contraception\n\n          -  Antioxidant drug and/or supplements six months previous to enrollment\n\n          -  Renal and/or hepatic failure\n\n          -  Age under 30 or over 75 years\n\n          -  Severe cardiovascular disease (myocardial infarction, stroke, severe peripheral\n             vasculopathy)\n\n          -  Blood dyscrasias\n\n          -  Have or have had cancer or other serious illness\n\n          -  Neurodegenerative process\n\n          -  Allergy to vitamins"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062034", 
            "org_study_id": "RDNP-20100102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ubiquinone", 
                "description": "400mg daily of oral ubiquinone for 24 weeks", 
                "intervention_name": "Ubiquinone", 
                "intervention_type": "Drug", 
                "other_name": "coenzyme Q10"
            }, 
            {
                "arm_group_label": "Combined antioxidant therapy", 
                "description": "(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one  Tablet for 24 weeks", 
                "intervention_name": "Combined antioxidant therapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "lutein", 
                    "zeaxanthin", 
                    "astaxanthin", 
                    "vitamin C", 
                    "vitamin E", 
                    "zinc", 
                    "copper"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Inactive drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antioxidants", 
                "Ascorbic Acid", 
                "Vitamin E", 
                "Alpha-Tocopherol", 
                "Tocopherols", 
                "Tocotrienols", 
                "Vitamins", 
                "Coenzyme Q10", 
                "Copper", 
                "Ubiquinone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Oxidative stress", 
            "Mitochondrial dysfunction", 
            "Ubiquinone", 
            "Antioxidant combined therapy", 
            "Diabetic retinopathy"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "link": {
            "description": "The effect of rosuvastatin in Diabetic Polyneuropathy: A Phase 2a Randomized Double-blind Placebo-controlled Study", 
            "url": "http://clinicaltrials.gov/ct2/show/record/NCT01622777"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Guadalajara", 
                    "country": "Mexico", 
                    "state": "Jalisco", 
                    "zip": "44340"
                }, 
                "name": "Cardiovascular Research Unit, University of Guadalajara"
            }
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study", 
        "other_outcome": {
            "description": "In this study the security profile markers are composed of intraocular pressure, visual acuity, renal function, and liver profile.\nIntraocular pressure. expressed in mmHg (baseline and final values) Visual acuity measured in decimal scale (baseline and final values) Renal function: serum urea (mg/dL), serum creatinine (mg/dL). (Baseline and final values) Liver profile: total serum bilirubin (mg/dL), indirect bilirubin (mg/dL), direct bilirubin (mg/dL)  (Baseline and final values).", 
            "measure": "Security profile", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Guadalajara", 
                "last_name": "Alejandra G. Miranda-D\u00edaz, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of Guadalajara", 
                "last_name": "Jos\u00e9 A. Castellanos-Gonz\u00e1lez, M.Sc.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Guadalajara", 
                "last_name": "Adolfo D. Rodriguez-Carrizalez, M.Sc.", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Mexico: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "In this study the oxidative stress markers are composed  of lipid peroxidation, nitric oxide, erythrocyte glutathion peroxidase activity, erythrocyte catalase activity, total antioxidant capacity and erythrocyte membrane fluidity.\nLipid peroxidation  (baseline and final values) given as malondialdehyde (MDA) and 4-hydroxyalkenals (4HDA) expressed in \u03bcmol/L\nNitric oxide (NO) Levels of the NO catabolites nitrites/nitrates expressed in pmol/mL (baseline and final values)\nErythrocyte glutathion peroxidase activity measured in U/min/mg protein (baseline and final values)\nErythrocyte catalase activity  expressed in U/mg protein (baseline and final values)\nTotal antioxidant capacity  measured in milliequivalent/mL (baseline and final values)\nErythrocyte membrane fluidity, calculated using the fluorescence ratio of the excimer (Ie) to monomer (Im).  The Ie/Im ratio.", 
            "measure": "Oxidative Stress markers", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062034"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Guadalajara", 
            "investigator_full_name": "Alejandra Guillermina Miranda Diaz", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "22595020", 
            "citation": "Hern\u00e1ndez-Ojeda J, Cardona-Mu\u00f1oz EG, Rom\u00e1n-Pintos LM, Troyo-Sanrom\u00e1n R, Ortiz-Lazareno PC, C\u00e1rdenas-Meza MA, Pascoe-Gonz\u00e1lez S, Miranda-D\u00edaz AG. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J Diabetes Complications. 2012 Jul-Aug;26(4):352-8. doi: 10.1016/j.jdiacomp.2012.04.004. Epub 2012 May 16."
        }, 
        "secondary_outcome": [
            {
                "description": "In this study the mitochondrial dysfunction markers are composed of hydrolysis of adenosine triphosphate and membrane fluidity in submitochondrial particles of platelets.\nHydrolysis of adenosine triphosphate: The hydrolytic activity of mitochondrial F0/F1-ATPase (F0/F1-adenosine triphosphatase) was measured as the liberation of inorganic phosphate from platelet mitochondria. Expressed in nmol of phosphate.  Baseline and final values.\nMembrane fluidity in submitochondrial particles of platelets. Calculated usig the fluorescence ratio of the excimer (Ie) to monomer (Im). The Ie/Im ratio. (Baseline and final values)", 
                "measure": "Mitochondrial dysfunction markers", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Evaluated with International clinical diabetic retinopathy disease severity scale, fluorescein angiography and color fundus photographs.\nBaseline and final stage.", 
                "measure": "Progression and regression of non-proliferative diabetic retinopathy", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "University of Guadalajara", 
        "sponsors": {
            "collaborator": {
                "agency": "Instituto Mexicano del Seguro Social", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Guadalajara", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}